Pharmaceutical compositions containing sterol inhibitors
Pharmaceutical compositions containing ezetimibe or its pharmaceutically acceptable salt that is substantially free of microcrystalline cellulose or crystalline cellulose are disclosed. Also disclosed are pharmaceutical compositions containing micronized particles of ezetimibe.
1 . A pharmaceutical composition comprising ezetimibe or a pharmaceutically acceptable salt thereof which is substantially free of microcrystalline cellulose or crystalline cellulose.
2 . The pharmaceutical composition of claim 1 , further comprising at least one excipient selected from the group consisting of a diluent, disintegrant, binder, lubricant and mixtures thereof.
3 . The pharmaceutical composition of claim 2 , wherein the diluent is selected from the group consisting of lactose, dicalcium phosphate, calcium sulfate, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, powdered sugar and mixtures thereof.
4 . The pharmaceutical composition of claim 2 , wherein the disintegrant is selected from the group consisting of carboxymethylcellulose calcium, carboxymethylcellulose sodium, sodium starch glycolate, crospovidone, guar gum, magnesium aluminum silicate, methyl cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, starch and mixtures thereof.
5 . The pharmaceutical composition of claim 2 , wherein the binder is selected from the group consisting of polyvinylpyrrolidone, starch mucilage, pregelatinized starch, sodium alginate, alginic acid, acacia mucilage, tragacanth, hydroxypropyl methyl cellulose, carboxymethylcellulose sodium, carboxymethylcellulose calcium, ethyl cellulose, polyethylene glycol, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polymethacrylate, carboxyvinyl polymers and mixtures thereof.
6 . The pharmaceutical composition of claim 2 , wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, zinc stearate and mixtures thereof.
7 . The pharmaceutical composition of claim 1 , comprising ezetimibe, lactose monohydrate, crospovidone, sodium lauryl sulphate, Povidone K-30 and magnesium stearate.
8 . The pharmaceutical composition of claim 1 , comprising ezetimibe, lactose monohydrate, sodium starch glycolate, sodium lauryl sulphate, Povidone K-30 and magnesium stearate.
9 . The pharmaceutical composition of claim 1 , in the form of a powder, tablet or a capsule.
10 . A pharmaceutical composition comprising micronized particles of ezetimibe or a pharmaceutically acceptable salt thereof, wherein about 90% of the ezetimibe particles are not more than about 25 microns.
11 . The pharmaceutical composition of claim 10 , wherein about 90% of the ezetimibe particles are not more than about 15 microns.
12 . The pharmaceutical composition of claim 10 , wherein about 90% of the ezetimibe particles are not more than about 10 microns.
13 . The pharmaceutical composition of claim 10 , wherein about 90% of the ezetimibe particles are not more than about 7 microns.
14 . The pharmaceutical composition of claim 10 , wherein about 50% of the ezetimibe particles are not more than about 10 microns.
15 . The pharmaceutical composition of claim 10 , wherein about 50% of the ezetimibe particles are not more than about 7 microns.
16 . The pharmaceutical composition of claim 10 , wherein about 50% of the ezetimibe particles are not more than about 4 microns.
17 . The pharmaceutical composition of claim 10 , further comprising one or more pharmaceutically acceptable excipients.
18 . The pharmaceutical composition of claim 10 , which is substantially free of microcrystalline cellulose or crystalline cellulose.
19 . The pharmaceutical composition of claim 10 , in the form of a powder, tablet or a capsule.
20 . A process for preparing a pharmaceutical composition, the process comprising (a) sifting ezetimibe and a pharmaceutically acceptable excipient comprising at least one of a diluent and a disintegrant through a sieve having openings less than, or equal to, about 60 mesh; (b) mixing the particles passing through the sieve; (c) granulating the mixture of (b) using a granulating solution comprising at least one binder; (d) drying the granules; (e) lubricating the granules; and (f) compressing the lubricated granules into tablets.